To understand where investments are heading, we need to study the transition from access to information to the generation of insights.
The healthtech venture capital landscape has undergone a necessary “purge” over the past twenty-four months. The era of “GP FOMO”, where all start-up with a “.ai” suffix and a vague promise in health could obtain a high valuation, left room for a period of in-depth clinical and technical review. That said, we are talking about cycles, and several can overlap.
For the founders, this is a correction. We are moving from “healthtech 1.0”, largely centered on the digitalization of administrative tasks, to the industrialization of techbio. To understand where investments are heading, we need to study the transition from access to information to the generation of insights.
What’s No Longer in Demand: The Platform Dilemma
To understand what is trendy today, we must first define what is no longer trendy. For many VCs, UI platforms for patient management or generic telemedicine are no longer an investment thesis. These solutions have been essential during the pandemic, but are now considered commodities.
Additionally, “AI black boxes” have become a major obstacle. In the TechBio sector, showing a result is no longer enough. If a platform claims to identify a new therapeutic target without being able to provide a biologically plausible “why”, it fails the transparency test required by the pharmaceutical industry. Investors no longer buy magic tricks, but reproducible science.
There needs to be a credible evaluation framework. For example, to establish causality, the Bradford Hill criteria become a sort of litmus test that can support predictive products.
What’s Trending: The Rise of High-Fidelity Data Infrastructure
We are currently seeing a massive shift towards creating data assets. In tech, we often talk about data as the “new black gold”. In TechBio, on the other hand, poor quality data is a huge risk.
What’s attractive today are companies building high-fidelity data loops, even if that means less volume. These are platforms that do not just aggregate public datasets, often biased or incomplete, but which create proprietary, clean, structured and verified data.
VCs are looking for “data refineries”: companies capable of transforming the chaotic noise of biological research into a structured asset, truly usable to train predictive models.
The industrialization of drug discovery
The most promising category of techbio is the shift from “discovery as art” to “discovery as engineering problem.”
Historically, discovering a drug was a high-risk gamble: testing thousands of molecules in the hope that only one would succeed. Today, investors favor “In-Silico First” approaches. It is no longer just a matter of accelerating the process, but of de-risking the entire R&D cycle.
If a company can simulate the risk-benefit profile of a treatment even before any laboratory experimentation, it is no longer a simple start-up: it is an infrastructure for the entire pharmaceutical industry.
Specialized verticals: pharmacovigilance and longevity
Beyond discovery, two segments are experiencing strong growth:
AI-Driven Pharmacovigilance: As drugs reach the market faster, real-time monitoring of their safety and Real World Evidence (RWE) becomes essential. Investors are looking for solutions that can automate the detection of adverse events, integrating not only the event itself, but also its full context. The objective: to transform security from a regulatory cost center into a competitive advantage.
Biology of resilience: we observe a shift from the treatment of symptoms towards the understanding of biological “outliers”, these patients who defy the odds. Modeling resilience rather than disease constitutes a major entrepreneurial pivot that is attracting more and more visionary investors.
The Founder’s Advantage
The founders who succeed in this context will be those able to bridge the “language gap”. An excellent healthtech entrepreneur must master three dialects: that of the doctor (clinical results), that of the data scientist (algorithmic rigor) and that of the VC (scalability and economic unity).
The future of techbio lies in the next big platform capable of transforming treatment research into a predictable, reproducible and scalable engineering process. If you build the engine, investors will provide the fuel.
